Build A Bear Workshop Inc vs Nuvalent Inc — how do they compare? Build A Bear Workshop Inc trades at $33.54 (market cap $412.61M), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 23.8× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.8% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| BBW | NUVL | |
|---|---|---|
Market Cap | $412.61M | $9.81B |
Sector | Consumer Cyclical | Technology |
52-Week High | $75.85 | $123.96 |
52-Week Low | $29.84 | $72.16 |
Enterprise Value | $512.05M | $8.52B |
Dividend Yield | 2.8% | — |
Signals from Pluang's Aura AI — not financial advice
Build-A-Bear Workshop (BBW) trades at $33.62, down 2.32% with a bullish technical signal and strong valuation metrics including a P/E of 7.71 and P/S of 0.81. The company maintains solid profitability with 10.48% net margins and 35.87% ROE, while recent earnings have consistently beaten expectations. CEO transition to Chris Hurt in June 2026 and new product launches support growth initiatives.
BBW presents compelling value with analyst consensus target of $62.50 (86% upside) and 73% buy ratings. Strong fundamentals and debt-free balance sheet support long-term growth, though near-term headwinds include consumer spending pressure and international expansion execution risks.
Nuvalent (NUVL) trades at $123.94, showing minimal daily movement with a 0.03% gain. The stock is in focus following GSK's proposed acquisition at $124 per share, announced June 2026. Technically, the price is at the acquisition offer level with a bullish moving average signal but overbought RSI readings. Fundamentally, the company reports significant losses with negative ROE and ROA, while cash flow remains supported by financing activities.
The investment outlook is dominated by the pending acquisition, limiting upside beyond the offer price. Key risks include deal completion uncertainty and ongoing operational losses. Analyst sentiment is mixed with a slight hold bias, reflecting caution until transaction closure. Shareholder value hinges on successful deal execution amid financial challenges.
Trailing returns across standard periods
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →